Hameln Pharma Ltd

Information

Name

Hameln Pharma Ltd

Type

Company

Roles

Supplier

Company Size

Sme

Company Number

Incorporation Date

Website

http://www.hameln.co.uk

Address

Unit C, Nexus, Gloucester Business Park,

Gloucester, Gloucestershire,
GL3 4AG
United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Hameln Pharma Ltd
Sign up free

Contracts awarded to Hameln Pharma Ltd

The contracts that Hameln Pharma Ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 2 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 16

Generic, Branded Generic & Proprietary Medicinal Products - Group 16 (5762100)

£36,914,657
Award

Published 2 months ago

NHS National Generic Pharmaceuticals Wave 15b

NHS National Pharmaceuticals Generic Products – Wave 15b Offer reference number: CM/PHG/23/5698 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5698/01 – Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months) NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months) LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months) CM/PHG/23/5698/02 – Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months) CM/PHG/23/5698/03 – Hospital Only (Housekeeping) Products DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months) DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months) DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months)

£147
Award

Published 3 months ago

Gastrointestinal, Endocrine, Nutrition & Blood Medicines

This Framework Agreement is for the supply of Gastrointestinal, Endocrine, Nutrition & Blood Medicines to health boards across NHS Scotland. The Goods have been split into fourteen (14) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice.

£48,954,512
Award

Published 5 months ago

NHS National Framework - Generics Housekeeping/Supply Chain Resilience Products

Project title: NHS National Framework for the supply of Generics Housekeeping Products & Oral Products, commencing 1 June 2025 Offer reference number: CM/PHG/24/5720 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/24/5720/01 - Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st June 2025 to 31st May 2027 (24 months) NWLN: (Northwest and London North): 1st June 2025 to 31st May 2027 (24 months) LSNE: (London South and Northeast): 1st June 2025 to 31st May 2027 (24 months) CM/PHG/24/5720/02 - Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st June 2025 to 31st May 2026 (12 months) DNW (Northwest) & DLN (London North): 1st June 2025 to 31st January 2027 (20 months) DLS (London South) & DNE (Northeast): 1st June 2025 to 31st May 2026 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£11,656,086 Bids close: 8 months ago
Award

Published 5 months ago

NHS National Framework for the supply of Generics Housekeeping / Supply Chain Resilience Products, commencing 1 June 2025

Project title: NHS National Framework for the supply of Generics Housekeeping / Supply Chain Resilience Products, commencing 1 June 2025 Offer reference number: CM/PHG/24/5720 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/24/5720/01 – Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st June 2025 to 31st May 2027 (24 months) NWLN: (Northwest and London North): 1st June 2025 to 31st May 2027 (24 months) LSNE: (London South and Northeast): 1st June 2025 to 31st May 2027 (24 months) CM/PHG/24/5720/02 – Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st June 2025 to 31st May 2026 (12 months) DNW (Northwest) & DLN (London North): 1st June 2025 to 31st January 2027 (20 months) DLS (London South) & DNE (Northeast): 1st June 2025 to 31st May 2026 (12 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£36
Award

Published 5 months ago

NP35925 Cardiovascular & Respiratory Medicines

This Framework Agreement is for the supply of Cardiovascular & Respiratory Medicines to health boards across NHS Scotland. The Goods have been split into nineteen (19) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice.

£82,305,880

Contacts

+44 1452621661

Statistics (1 Year)

Contracts Won

Total Won

£47,508,605

Average Win

£23,754,303

Hameln Pharma Ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Hameln Pharma Ltd

Generic, Branded Generic & Proprietary Medicinal Products - Group 16

NHS National Generic Pharmaceuticals Wave 15b

Gastrointestinal, Endocrine, Nutrition & Blood Medicines

NHS National Framework - Generics Housekeeping/Supply Chain Resilience Products

NHS National Framework for the supply of Generics Housekeeping / Supply Chain Resilience Products, commencing 1 June 2025

NP35925 Cardiovascular & Respiratory Medicines

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win